Clinical Study

A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes

Table 3

Glycemic excursion parameters at the end of treatment with continuous subcutaneous insulin infusion (group A) or basal insulin glargine plus oral hyperglycemic agent (group B).

IndicesGroup A ()Group B () value for group comparison

MAGE (mmol/L)3.40 ± 1.403.16 ± 1.380.484
SDBG1.41 ± 0.531.21 ± 0.530.119
FGE3 (3–4)3 (3–4)0.908
MODD1.64 ± 0.551.54 ± 0.750.520
AUC < 3.90.00 (0.00–0.02)0.00 (0.00–0.00)0.142
AUC > 7.80.46 ± 0.370.24 ± 0.180.003
1-hour prebreakfast MBG (mmol/L)7.11 ± 1.206.26 ± 1.170.004
1-hour prelunch MBG (mmol/L)7.24 ± 1.716.46 ± 1.440.047
1-hour predinner MBG (mmol/L)7.78 ± 1.586.69 ± 1.190.002
3-hour after breakfast MBG (mmol/L)7.56 ± 1.237.18 ± 1.230.207
3-hour after lunch MBG (mmol/L)7.84 ± 1.646.98 ± 1.360.021
3-hour after dinner MBG (mmol/L)8.08 ± 1.437.52 ± 1.410.111
24-hour MBG (mmol/L)7.49 ± 0.967.02 ± 1.030.056

Data are mean (standard deviation) unless otherwise stated. Median (range) AUC > 7.8 mmol/L, area under the curve above 7.8 mmol/L; AUC < 3.9 mmol/L, area under the curve below 3.9 mmol/L. MBG: mean blood glucose; SDBG: standard deviation of blood glucose; MAGE: mean amplitude of glycemic excursions; FGE: frequency of glycemic excursion; MODD: mean of daily differences.